Farsad Afshinnia1, Ka Kit Wong1, Baskaran Sundaram1, Robert J Ackermann1, Subramaniam Pennathur1. 1. Division of Nephrology (F.A., S.P.), Department of Internal Medicine, Department of Nuclear Medicine/Radiology (K.K.W., R.J.A.), University of Michigan, Ann Arbor, Michigan 48109; Veterans Affairs Ann Arbor Healthcare System (K.K.W.), Ann Arbor, Michigan 48105; and Division of Radiology (B.S.), Thomas Jefferson University, Philadelphia, Pennsylvania 19107.
Abstract
CONTEXT: Human studies have reported conflicting results on the association of hypoalbuminemia with osteoporosis. OBJECTIVE: The aim of the study is to test the independent association between hypoalbuminemia and osteoporosis. DESIGN: This is a cross-sectional observation. SETTING AND PARTICIPANTS: Patients are the outpatient consecutive individuals with available clinical, laboratory, and densitometry data from 2001 to 2013 in our tertiary care academic medical center. EXPOSURE: Exposure is hypoalbuminemia defined as serum albumin less than 3.5 g/dL. MAIN OUTCOME MEASURE: Osteoporosis is defined as bone mineral density of 2.5 SD or less below the mean peak bone mass of young, healthy adults. RESULTS: Overall, 21 121 patients were included. Mean of age was 61 years (SD 14). There were 4244 males (20.1%) and 1614 patients of African-American ethnicity (7.6%). There was a graded decrease in rate of osteoporosis from 28.0% (n = 33) at albumin of 3 g/dL or less to 9.3% (n = 1548) at albumin greater than 4 g/dL (P < .001) at the femoral neck and from 20.3% (n = 24) to 6.1% (n = 1011) at the total hip (P < .001). In a fully adjusted model, the odds of osteoporosis at albumin of 3 g/dL or less was 3.31-fold (95% confidence interval [CI] 2.08-5.28, P < .001) at the femoral neck, 2.98-fold (95% CI 1.76-5.01, P < .001) at the total hip, and 2.18-fold (95% CI 1.43-3.31, P < .001) at the lumbar spine as compared with albumin greater than 4 mg/dL. A similar independent association was identified with a longer-observed duration of hypoalbuminemia. CONCLUSION: In a large population, we report an independent association of osteoporosis with lower levels of serum albumin and a longer-observed duration of hypoalbuminemia.
CONTEXT: Human studies have reported conflicting results on the association of hypoalbuminemia with osteoporosis. OBJECTIVE: The aim of the study is to test the independent association between hypoalbuminemia and osteoporosis. DESIGN: This is a cross-sectional observation. SETTING AND PARTICIPANTS: Patients are the outpatient consecutive individuals with available clinical, laboratory, and densitometry data from 2001 to 2013 in our tertiary care academic medical center. EXPOSURE: Exposure is hypoalbuminemia defined as serum albumin less than 3.5 g/dL. MAIN OUTCOME MEASURE: Osteoporosis is defined as bone mineral density of 2.5 SD or less below the mean peak bone mass of young, healthy adults. RESULTS: Overall, 21 121 patients were included. Mean of age was 61 years (SD 14). There were 4244 males (20.1%) and 1614 patients of African-American ethnicity (7.6%). There was a graded decrease in rate of osteoporosis from 28.0% (n = 33) at albumin of 3 g/dL or less to 9.3% (n = 1548) at albumin greater than 4 g/dL (P < .001) at the femoral neck and from 20.3% (n = 24) to 6.1% (n = 1011) at the total hip (P < .001). In a fully adjusted model, the odds of osteoporosis at albumin of 3 g/dL or less was 3.31-fold (95% confidence interval [CI] 2.08-5.28, P < .001) at the femoral neck, 2.98-fold (95% CI 1.76-5.01, P < .001) at the total hip, and 2.18-fold (95% CI 1.43-3.31, P < .001) at the lumbar spine as compared with albumin greater than 4 mg/dL. A similar independent association was identified with a longer-observed duration of hypoalbuminemia. CONCLUSION: In a large population, we report an independent association of osteoporosis with lower levels of serum albumin and a longer-observed duration of hypoalbuminemia.
Authors: B Fibbi; S Benvenuti; C Giuliani; C Deledda; P Luciani; M Monici; B Mazzanti; C Ballerini; A Peri Journal: Endocrine Date: 2015-06-21 Impact factor: 3.633
Authors: V Korkmaz; Z Kurdoglu; M Alisik; E Turgut; O O Sezgın; H Korkmaz; Y Ergun; O Erel Journal: J Endocrinol Invest Date: 2016-11-17 Impact factor: 4.256
Authors: Robert Wakolbinger; Christian Muschitz; Jacqueline Wallwitz; Gerd Bodlaj; Xaver Feichtinger; Jakob E Schanda; Heinrich Resch; Andreas Baierl; Peter Pietschmann Journal: Wien Klin Wochenschr Date: 2020-01-07 Impact factor: 1.704
Authors: Hannes Zwickl; Elisabeth Zwickl-Traxler; Alexander Haushofer; Josef Seier; Klaus Podar; Michael Weber; Klaus Hackner; Nico Jacobi; Martin Pecherstorfer; Sonia Vallet Journal: BMC Cancer Date: 2021-06-28 Impact factor: 4.430
Authors: Cai Mei Zheng; Chia Chao Wu; Chien Lin Lu; Yi Chou Hou; Mai Szu Wu; Yung Ho Hsu; Remy Chen; Tian Jong Chang; Jia Fwu Shyu; Yuh Feng Lin; Kuo Cheng Lu Journal: Int J Med Sci Date: 2019-10-21 Impact factor: 3.738